SAGE Therapeutics (SAGE) Misses Q2 EPS by 6c; Readout of Phase 3 STATUS Trial in SRSE Now Expected in 1H 2017

August 9, 2016 6:43 AM EDT
Get Alerts SAGE Hot Sheet
Price: $49.02 --0%

Today's EPS Names:
GWPH, KZ, More
Trade SAGE Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($1.08), $0.06 worse than the analyst estimate of ($1.02).

  • Portfolio Expansion Underway Based on Recent Positive Data from SAGE-547 and SAGE-217
  • Top-line Data Readout of Phase 3 STATUS Trial in SRSE Now Expected in 1H 2017
  • Dosing Commenced in Expanded Phase 2 Program for SAGE-547 in Moderate and Severe Postpartum Depression
  • Phase 2 Initiations Planned for SAGE-217 in Essential Tremor and Postpartum Depression in 2H 2016
  • Proof-of-Concept Study Initiations Planned with SAGE-547 in Major Depressive Disorder and SAGE-217 in Parkinson’s Disease in 2H 2016

Cash, cash equivalents and marketable securities as of June 30, 2016 were $272.3 million, compared with $186.8 million at December 31, 2015.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Earnings, FDA

Related Entities

Earnings

Add Your Comment